Neurotech Policy James J. Hughes Ph.D. Executive Director, Institute for Ethics and Emerging Technologies Public Policy Studies, Trinity College, Hartford.

Slides:



Advertisements
Similar presentations
Consumer Safety and Drug Regulations
Advertisements

The Transhuman and the Fourth Decade Effect: Evolution of Insurance for the Future Chief Strategy Officer, EFU Life Assurance Ltd Actuarial Conference.
Waiting for the Great Leap… Forward? J. Hughes - Institute for Ethics and Emerging Technologies - Trinity College.
© American Telemedicine Association Telemedicine Today Jonathan D. Linkous, CEO American Telemedicine Association.
Neuroethics: What is it and what comes next? Françoise Baylis, PhD; Professor Canada Research Chair in Bioethics and Philosophy.
Introduction to Regulation
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
COMPUTER AND INFORMATION ETHICS By: Richard Ramos.
Human Embryo Research James G. Anderson, Ph. D Purdue University.
What Do Toxicologists Do?
Prosthetic Ethics James J. Hughes Ph.D. Executive Director, Institute for Ethics and Emerging Technologies Public Policy Studies, Trinity College, Hartford.
Recreational Therapy: An Introduction Chapter 9: Geriatric Practice PowerPoint Slides.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Michael P. Kilgard Healing the Human Brain: The Next Medical Revolution University of Texas at Dallas.
James J. Hughes Ph.D. Executive Director, Institute for Ethics and Emerging Technologies Public Policy Studies, Trinity College, Hartford CT
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.
Responsible Conduct of Research (RCR) Farida Lada October 16, 2013
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Copyright Institute for Ethics and Emerging Technologies 2007 Cyborgs Today & in the Future Transvision 2007 James J. Hughes Ph.D. Author Citizen Cyborg.
Copyright Institute for Ethics and Emerging Technologies 2005 Democracy, Citizenship and Universal Access to Safe Enhancement James J. Hughes Ph.D. Executive.
INTRODUCTION TO RA.
The Changing Information Needs of Public Health Kimberley Shoaf, DrPH Director.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
HUMAN RESEARCH HISTORICAL PERSPECTIVE. Objectives Identify the history events that lead to the development of principles, regulations, and guidance.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
Chapter 6 – Data Handling and EPR. Electronic Health Record Systems: Government Initiatives and Public/Private Partnerships EHR is systematic collection.
Institute for Ethics and Emerging Technologies We Can Be Smarter and Happier: The Future of Neurotechnology James J. Hughes Ph.D. Executive Director, Institute.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
1 Post-Genomics and the Future of Human Societies: a Foresight Approach Excerpts from “ DNA Analysis for Human Health in the Post- Genomic Era - An APEC-wide.
Information Ethics Prof. Madya Dr. Rozinah Jamaludin 11 March 2010.
Institute for Ethics and Emerging Technologies Cognitive Liberty in the Neurotechnology Era James J. Hughes Ph.D. Executive Director, Institute for Ethics.
1. Amped 2 Daniel H. Wilson, Amped (2012) & Benedict Carey, Probing Brain’s Depth, Trying to Aid Memory. New York Times, July 9, 2014Trying to Aid Memory.
Senior MESA Day.  Application of engineering technology to fields of medicine and biology.  Combines design and problem solving skills of engineering.
Defining Disability in an Age of Enhancement James J. Hughes Ph.D. Public Policy Studies Trinity College Union College – May.
Transcranial Magnetic Stimulation (TMS)
Collaboration in eRegion- ICT for Growth and Empowerment Bror Salmelin Head of Unit, New working environments European Commission, DG Information Society.
Dynamics of Care in Society 2 Health Care & Technology.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.1: Unit 2: Health Care Settings 1.2 a: Overview and the Organization of Federal.
Community Health. Something to think about...  What are the different agencies that provide for the community locally, nationally, and globally?
PHARMACY LAWS.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
An Innovative Mental Health Center. Reasons for HOPE: Advances in Mental Health Care Presented by Paul E. Keck, Jr., M.D. President and Chief Executive.
The NIMH Research Domain Criteria Initiative (RDoC): A Framework for Psychopathology Research February 20, 2014 Jill Heemskerk, PhD Deputy Director, Division.
ETHICS IN BIOMEDICAL ENGINEERING BY RYAN IVONE. INTRODUCTION Goal : Use their knowledge, skills, and abilities to enhance the safety, health, and welfare.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
The Emergence of Therapeutic Neurostimulation: Reducing Barriers to Innovation and Growth John Reppas MD- PhD Director of Public Policy American Society.
6 - 1 Introduction to US Health Care Chapter 6 Research and Technology.
6 - 1 Introduction to US Health Care HS230 Health Care Administration Kaplan University Unit 7: Research & Technology Chapter 6 Kathy Lantz, MHS, MBA.
1 Dr David Coles Ethics and Science European Commission ACTIVITIES on ETHICS in The Science and Society Programme.
Technology is Good for Healthy Longevity
ETHICAL ISSUES WITH ARTIFICIAL INTELLIGENCE
The Nervous System Ch. 9 Lesson 2
Issues and Fields in Psychology
The Information Professional’s Role in Product Safety
Research Overview Jacqueline French, MD Chief Scientific Officer
ETHICAL ISSUES WITH ARTIFICIAL INTELLIGENCE
Chapter 7 The Health Care System
Government Regulations for Disease Prevention
Issues and Fields in Psychology
FDA Sentinel Initiative
Opening an IND: Investigator Perspective
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Issues and Fields in Psychology
Research, Experimentation, & Clinical Trials
Issues and Fields in Psychology
Careers in Psychology Module 3.
Chapter 7The Health Care System
Presentation transcript:

Neurotech Policy James J. Hughes Ph.D. Executive Director, Institute for Ethics and Emerging Technologies Public Policy Studies, Trinity College, Hartford CT January 10, 2012 Trinity College, Hartford CT

Institute for Ethics and Emerging Technologies Broad Frame for Neurotech Internal External HardwareSoftware

Institute for Ethics and Emerging Technologies External Hardware Pictures, written language and numbers outsourced the brain Started with clay and paper Today wearable computers Smart phones Aug cog The wireless exo-cortex

Institute for Ethics and Emerging Technologies External Software Communication with other people: verbal, electronic Collaborative knowledge: Meetings, Markets, Wikipedia, Google Calendars & To do lists Info visualization Biofeedback Expert systems and intelligent agents

Institute for Ethics and Emerging Technologies Internal Hardware Nutritional supplements Clinical drugs Stem cells and tissue engineering Deep brain stimulation Gene therapies Brain-computer interfaces Transcranial magnetic stimulation Nanorobotics

Copyright Institute for Ethics and Emerging Technologies 2005 Countervailing Influences Science Policy Consumer Lobbies Industry Lobbies (Phrma, NIO, etc) Experts (NAS, etc.) Medical Associations (AMA, etc) Thinktanks (Brookings, AEI, Cato, etc.)

Points of Influence Institute for Ethics and Emerging Technologies 2012 NIH/NIMH funding of basic research Private investment Product Development FDA Clinical Trials Development of Standards of Care Public Insurance Coverage Private Insurance Coverage Post Approval Surveillance and Research DEA/criminal control of off- label use and illegal drugs

Copyright Institute for Ethics and Emerging Technologies 2005 Pro-Science Citizen Lobbies Disease lobbies JDRF, ACT-UP, Alzheimers Stem cell research lobby groups State stem cell funding campaigns Consumer protection groups Critiquing politicized science policy Anti-psychiatry groups Mental patients rights, Aspie rights, Scientology

Institute for Ethics and Emerging Technologies 2012 Neuroprosthetics & NNI NIH Neural Prosthesis Program Cochlear & retinal implants Peripheral neural prosthetics Brain implants National Nanotechnology Program Ethical, Legal and Other Societal Issues

Institute for Ethics and Emerging Technologies 2012 Prosthetic Limbs Indirect neural control Direct neural control Haptic feedback

Institute for Ethics and Emerging Technologies 2012 NBIC Convergence Nano-Bio-Info-Cogno Program (2003-) Psychopharmacology Genetic engineering Nanotechnology Artificial intelligence Cognitive science The accelerating convergence of all these for “enhancing human performance”

Institute for Ethics and Emerging Technologies 2011 Cognos and Brain Modeling Modeling brain systems and cognitive processes will allow rapid testing of neurotechnology Blue Brain Project (IBM, Swiss) Cognos Project Finetuning of evolving exocerebrum against models of the neocortex

Institute for Ethics and Emerging Technologies 2012 Tissue Engineering Stem cells engineered into therapeutic neural tissue Nanomaterials as scaffolding and mesh around which stem cells can grow tissues and neural bridges Using electrical stimulation of cells through the mesh to control the growth of the tissue

Institute for Ethics and Emerging Technologies 2012 Deep Brain Stimulation Depression Obsessive-compulsive disorder 1% of the population has seizure disorders, such as Epilepsy Parkinsons Disease

Institute for Ethics and Emerging Technologies 2012 Cochlear and Visual Implants By 2010, approximately 219,000 people worldwide received cochlear implants. In US, 42,600 adults and 28,400 children received them.

Institute for Ethics and Emerging Technologies 2012 Brain Damage & Neuroprosthetics Post-stroke brain injury is leading cause of disability in U.S. One in 250 suffer from the effects of head injuries About 750,000 people with cerebral palsy in the U.S. About 75,000 quadriplegics in the U.S. Lou Gehrig's Disease or ALS and muscular dystrophy each effects about 15,000 Americans “Locked-in state” Neuro-regenerative Rx Neuroprosthetics

Institute for Ethics and Emerging Technologies 2012 Brain-Computer Interfaces

Institute for Ethics and Emerging Technologies 2012 NanoNeural Robotics Ray Kurzweil 2030s? Self-replicating Two-way communication with trillions of neurons Networked inside and out Perfect virtual reality, mind back-up, upload

Non-Problems & Old Problems Some ethical issues are false problems, at least from an Enlightenment POV Others are old problems, like ensuring safety and access A few are novel because of the efficacy of neuroprosthetics Institute for Ethics and Emerging Technologies 2012

Non-Problems Supersoldiers Sports enhancement Disappearing disabled cultures Authenticity Institute for Ethics and Emerging Technologies 2012

SuperSoldiers Ethics of military force, or of military applications Does neurotech change likelihood of exploiting soldiers as guinea pigs or in the field ability to exercise judgment in field, reduce collateral damage (drones) likelihood of engaging in conflicts Institute for Ethics and Emerging Technologies 2012

Sports Enhancement ADD drugs? Sports is a rule- governed game If athletes want to use neurotechnology to compete they can start their own leagues Not relevant to society Institute for Ethics and Emerging Technologies 2012

Disappearing Disabilities 99% of disabled happy to give up their disabilities Only children forced to use Last century: dramatic decline in veteran and civilian amputees 1000 amputees from Iraq/Afghan vets surgeons in Civil War, 60,000+ amputees Changes cost-benefit analysis for social priority-setting (Loeb) Difficulty in commercializing the direct neural control prosthethics developed by DARPA or others Institute for Ethics and Emerging Technologies 2012

“Authenticity” Avoidance of SSRIs, ADD drugs Not human, not me But Self image is malleable Prosthetics easily incorporated Institute for Ethics and Emerging Technologies 2012

Old Problems Safety of devices Autonomy and addiction Moving line between disability/normal/ enhanced Unequal access Ownership & intellectual property Privacy & cybersecurity Institute for Ethics and Emerging Technologies 2012

Safety Federal Food, Drug, and Cosmetic Act covers all implants and other devices "intended to affect the structure or any function of the body of man or other animals“ But FDA’s 510k (similar to prior approval) loophole Center for Devices and Radiological Health underfunded to handle scope and pace of innovation Authority inadequate to gather clinical trial information or compel reporting of post-approval adverse events Institute for Ethics and Emerging Technologies 2012 Are military IRBs’ reviews adequate to protect soldiers from experimental technologies

(Il)legal Psychoactive Drugs DEA has 5 categories of scheduled drugs, then over the counter

Copyright Institute for Ethics and Emerging Technologies 2005 Data Censoring by Investigators The aggregation of experimental outcomes by health systems Assure completeness of result reporting

Autonomy & Addiction Remote behavior control of criminals, soldiers, astronauts Wireheading: mood control Blurred culpability: developer, software, user Institute for Ethics and Emerging Technologies 2012

Copyright Institute for Ethics and Emerging Technologies 2005 Home Health Monitoring Telemedicine Wireless devices, linked to health system Blood Pressure Monitors Glucometers Peak Flow Meters Pulse Oximeters Weight Scale

Defining Disabled/Enhanced When Medicare changed its definition for coverable cochlear implants from deafness to severe hearing loss it expanded coverage for millions of seniors Similar fights over Depression (transient grief) vs. mood enhancement Attention-deficit vs. performance enhancement Institute for Ethics and Emerging Technologies 2012

Superhuman Abilities 5% to 35% college students use off-label stimulants as study aids Institute for Ethics and Emerging Technologies 2012

Modafinil (Provigil) Developed and approved as treatment for narcolepsy and “excessive day-time sleepiness” Schedule 4 controlled substance

Diagnostic Creation of ADD 1930s stimulants prescribed to treat “minimal brain dysfunction” 1960s “minimal brain dysfunction” “learning/behavioral disabilities” and “hyperactivity” Ritalin synthesized in 1950s, prescribed in 1960s DSM-II (1968): “Hyperkinetic Reaction of Childhood” DSM-III (1980): “ADD (Attention-Deficit Disorder) with or without hyperactivity” DSM-III-R (1987): “ADHD” ICD-10: “Hyperkinetic disorders” DSM-IV criteria diagnose 4x more ADHD than the stricter ICD-10 criteria

Unequal Access In every other industrialized country the debate is what should be in or out of the plan Here it is up to 1500 private and 60 or so public insurance plans Critical: Speed of innovation of cheap versions Institute for Ethics and Emerging Technologies 2012

Ownership & Property Human gene patenting Pharmaceutical and neurodevice patent overreach Expansion of Chinese neurotech device production (e.g. Medtronic) International IP Protection Humanitarian exemption and pricing Institute for Ethics and Emerging Technologies 2012

Copyright Institute for Ethics and Emerging Technologies 2005 International Harmonization Harmonization of regulation within the OECD (including Japan) will speed innovation Global Harmonization Task Force (Devices) International Conference on Harmonization (Drugs)

Privacy and Cybersecurity Already issue with mobile technology and RFID Privacy of biometric information - controversy in 2002 over the VeriChip patient ID and tracking system Implanted medical records, e-cash, telecom Battlefield biotelemetry Wireless hacking of prosthetics (Jay Radcliffe: insulin pump hacking) Self-hacking to control drug administration Required registration of high-power prosthetics Institute for Ethics and Emerging Technologies 2012 National security secrecy and corporate IP inhibit open source innovation, translation to application See: 2005 EU Report “Ethical Aspects of ICT Implants in the Human Body”

Newer Problems Timing of implants and upgradeability Structural unemployment Remote behavior control Mood control Blurred culpability Institute for Ethics and Emerging Technologies 2012

Timing of Implants Accelerating pace of innovation Especially rapid advances in biocompatible materials Cochlear implants Critical language window Destruction of cochlear tissue Institute for Ethics and Emerging Technologies 2012

Structural Unemployment Prior cases: literate/numerate workers Digital divide smartphones Competing not only against automation and globalization, but also against brain-machine enhanced workers (vets?) Cog enhancement drugs AugCog Institute for Ethics and Emerging Technologies 2012

Neuropolicy Organizations International Society for Neuroethics Dana Foundation MacArthur Foundation Network on Law and Neuroscience Center for Neurotechnology Studies, Potomac Institute for Policy Studies in Arlington, Virginia Neurotechnology Industry Organization Institute for Ethics and Emerging Technologies 2012

Neuropolicy Experts Walter Glannon, Philosophy, University of Calgary David Eagleman, Neuroscience, Baylor College of Medicine Jonathan Moreno, Center for American Progress Martha Farah, Upenn Center for Neuroscience and Society Hank Greely, Stanford Program in Neuroethics Judy Illes, Chair in Neuroethics, Univ of British Columbia Michael Gazzaniga, Cognitive Neuroscience, Dartmouth College Zach Lynch, Neurotechnology Industry Organization Diana Zuckerman, Alliance for a Stronger FDA Institute for Ethics and Emerging Technologies 2012

For more information Institute for Ethics and Emerging Technologies ieet.org Me: These slides: